RPTX - REPARE ALERT: Bragar Eagel & Squire P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX) on behalf of Repare stockholders. Our investigation concerns whether Repare has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On February 12, 2024, Repare issued a press release "announc[ing] . . . that it will regain global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and ...